An update from Innovent Biologics ( (HK:1801) ) is now available.
Innovent Biologics has reported a significant improvement in its financial performance for the year ended December 31, 2024, with a 51.8% increase in revenue and a substantial narrowing of its IFRS loss by 90.8% year-over-year. The company achieved its first-ever positive Non-IFRS profit and EBITDA, driven by robust product revenue growth, increased license fee income, and operational improvements, marking a historic milestone since its listing on the Hong Kong Stock Exchange.
More about Innovent Biologics
Innovent Biologics, Inc. is a leading company in the biopharmaceutical industry, focusing on sustainable operations and global innovation. The company is known for its strong product revenue growth and commitment to research and development milestones.
YTD Price Performance: 15.17%
Average Trading Volume: 13,704
Technical Sentiment Signal: Sell
Current Market Cap: $8.25B
For a thorough assessment of 1801 stock, go to TipRanks’ Stock Analysis page.